Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies

Schizophrenia Research

Volumn 183, Issue , 2017, Pages 10-21

  Ostuzzi, Giovanni ^a   Bighelli, Irene ^a,b   So, Ryuhei ^c,d   Furukawa, Toshi A ^d   Barbui, Corrado ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Okayama Psychiatric Medical Center   (Japan)

^d KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antipsychotic formulation; Antipsychotic tolerability; Long acting injectable antipsychotics; Meta analysis; Schizophrenia; Systematic review

Indexed keywords

ARIPIPRAZOLE; BROMPERIDOL DECANOATE; FLUPENTIXOL DECANOATE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; FLUPHENAZINE ENANTHATE; FLUSPIRILENE; HALOPERIDOL; HALOPERIDOL DECANOATE; LONG ACTING DRUG; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE DECANOATE; PIPOTIAZINE PALMITATE; PIPOTIAZINE UNDECENOATE; PROLACTIN; RISPERIDONE; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL ACETATE; ZUCLOPENTHIXOL DECANOATE;

ADVERSE DRUG REACTION; BIPOLAR DISORDER; CLINICAL OUTCOME; DRUG EFFICACY; DRUG FORMULATION; DRUG QUALITY; DRUG RESEARCH; DRUG TOLERABILITY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; META ANALYSIS; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE RISK; REVIEW; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREATMENT RESPONSE; WEIGHT GAIN; DRUG DELIVERY SYSTEM; MENTAL DISEASE; ORAL DRUG ADMINISTRATION; PROCEDURES;

ADMINISTRATION, ORAL; ANTIPSYCHOTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; MENTAL DISORDERS;

EID: 85006757635     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2016.11.010     Document Type: Review

References (85)

1. Altman, D.G., Bland, J.M., Detecting skewness from summary information. BMJ, 313(7066), 1996, 1200.
2. Arango, C., Bombín, I., González-Salvador, T., García-Cabeza, I., Bobes, J., Randomised clinical trial comparing oral versus depot formulations of zuclopenthixol in patients with schizophrenia and previous violence. Eur. Psychiatry 21:1 (2006), 34–40, 10.1016/j.eurpsy.2005.07.006.
3. Bai, Y.M., Ting Chen, T., Chen, J.-Y., Chang, W.-H., Wu, B., Hung, C.H., Kuo Lin, W., Equivalent switching dose from oral risperidone to risperidone long-acting injection: a 48-week randomized, prospective, single-blind pharmacokinetic study. J. Clin. Psychiatry 68:8 (2007), 1218–1225.
4. Bak, M., Fransen, A., Janssen, J., van Os, J., Drukker, M., Zhang, X.Y., Almost all antipsychotics result in weight gain: a meta-analysis. PLoS One, 9(4), 2014, e94112, 10.1371/journal.pone.0094112.
5. Barbui, C., Sharing all types of clinical data and harmonizing journal standards. BMC Med., 14(1), 2016, 63, 10.1186/s12916-016-0612-8.
6. Barbui, C., Furukawa, T.A., Cipriani, A., Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials. CMAJ 178:3 (2008), 296–305, 10.1503/cmaj.070693.
7. Barbui, C., Dua, T., van Ommeren, M., Yasamy, M.T., Fleischmann, A., Clark, N., Thornicroft, G., Hill, S., Saxena, S., Challenges in developing evidence-based recommendations using the GRADE approach: the case of mental, neurological, and substance use disorders. PLoS Med., 7(8), 2010, 10.1371/journal.pmed.1000322.
8. Barbui, C., Gureje, O., Puschner, B., Patten, S., Thornicroft, G., Implementing a data sharing culture. Epidemiol. Psychiatr. Sci., 2016, 1–2, 10.1017/S2045796016000330.
9. Blanchet, P.J., Rompré, P.H., Clinimetric evaluation of the Simpson-Angus Scale in older adults with schizophrenia. J. Clin. Psychopharmacol. 34:1 (2014), 36–39, 10.1097/JCP.0b013e3182a6a2e3.
10. Brissos, S., Veguilla, M.R., Taylor, D., Balanza-Martinez, V., The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther. Adv. Psychopharmacol. 4:5 (2014), 198–219, 10.1177/2045125314540297.
11. Chue, P., Eerdekens, M., Augustyns, I., Lachaux, B., Molcan, P., Eriksson, L., Pretorius, H., David, A.S., Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. Eur. Neuropsychopharmacol. 15:1 (2005), 111–117, 10.1016/j.euroneuro.2004.07.003.
12. del Giudice, J., Clark, W.G., Gocka, E.F., Prevention of recidivism of schizophrenics treated with fluphenazine enanthate. Psychosomatics 16:1 (1975), 32–36.
13. Detke, H.C., Weiden, P.J., Llorca, P.-M., Choukour, M., Watson, S.B., Brunner, E., Ascher-Svanum, H., Comparison of olanzapine long-acting injection and oral olanzapine. J. Clin. Psychopharmacol. 34:4 (2014), 426–434, 10.1097/JCP.0000000000000140.
14. Emsley, R.A., Oosthuizen, P.P., Joubert, A.F., Hawkridge, S.M., Stein, D.J., Treatment of schizophrenia in low-income countries. Int. J. Neuropsychopharmacol. 2:4 (1999), 321–325, 10.1017/S1461145799001613.
15. Ereshefsky, L., Mascarenas, C.A., Comparison of the effects of different routes of antipsychotic administration on pharmacokinetics and pharmacodynamics. J. Clin. Psychiatry 64:Suppl. 16 (2003), 18–23.
16. Fleischhacker, W.W., Meise, U., Günther, V., Kurz, M., Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr. Scand. Suppl. 382 (1994), 11–15.
17. Fleischhacker, W.W., Sanchez, R., Perry, P.P., Jin, N., Peters-Strickland, T., Johnson, B.R., Baker, R.A., Eramo, A., McQuade, R.D., Carson, W.H., Walling, D., Kane, J.M., Aripiprazole once-monthly for treatment of schizophrenia: double-blind, randomised, non-inferiority study. Br. J. Psychiatry 205:2 (2014), 135–144, 10.1192/bjp.bp.113.134213.
18. Furukawa, T.A., Cipriani, A., Barbui, C., Brambilla, P., Watanabe, N., Imputing response rates from means and standard deviations in meta-analyses. Int. Clin. Psychopharmacol. 20:1 (2005), 49–52.
19. Furukawa, T.A., Barbui, C., Cipriani, A., Brambilla, P., Watanabe, N., Imputing missing standard deviations in meta-analyses can provide accurate results. J. Clin. Epidemiol. 59:1 (2006), 7–10, 10.1016/j.jclinepi.2005.06.006.
20. Gardner, D.M., Murphy, A.L., O'Donnell, H., Centorrino, F., Baldessarini, R.J., International consensus study of antipsychotic dosing. AJP 167:6 (2010), 686–693, 10.1176/appi.ajp.2009.09060802.
21. Green, A.I., Brunette, M.F., Dawson, R., Buckley, P., Wallace, A.E., Hafez, H., Herz, M., Narasimhan, M., Noordsy, D.L., O'Keefe, C., Sommi, R.W., Steinbook, R.M., Weeks, M., Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial. J. Clin. Psychiatry, 2015, 1359–1365, 10.4088/JCP.13m08838.
22. Guyatt, G.H., Oxman, A.D., Vist, G.E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., Schünemann, H.J., GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:7650 (2008), 924–926, 10.1136/bmj.39489.470347.AD.
23. Guyatt, G.H., Oxman, A.D., Kunz, R., Brozek, J., Alonso-Coello, P., Rind, D., Devereaux, P.J., Montori, V.M., Freyschuss, B., Vist, G., Jaeschke, R., Williams, J.W. Jr., Murad, M.H., Sinclair, D., Falck-Ytter, Y., Meerpohl, J., Whittington, C., Thorlund, K., Andrews, J., Schunemann, H.J., GRADE guidelines 6. Rating the quality of evidence-imprecision. J. Clin. Epidemiol. 64:12 (2011), 1283–1293, 10.1016/j.jclinepi.2011.01.012.
24. Haddad, P., Brain, C., Scott, J., Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. PROM, 43, 2014, 10.2147/PROM.S42735.
25. Haider, I., A controlled trial of fluphenazine enanthate in hospitalized chronic schizophrenics. Br. J. Psychiatry 114:512 (1968), 837–841.
26. Higgins, G., Cochrane handbook for systematic reviews of interventions. 2011, Wiley, Hoboken, N.J. (1 online resource).
27. Hogarty, G.E., Schooler, N.R., Ulrich, R., Mussare, F., Ferro, P., Herron, E., Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analyses of a two-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch. Gen. Psychiatry 36:12 (1979), 1283–1294.
28. Hosalli, P., Davis, J.M., Depot risperidone for schizophrenia. Cochrane Database Syst. Rev., 4, 2003, CD004161, 10.1002/14651858.CD004161.
29. Ishigooka, J., Nakamura, J., Fujii, Y., Iwata, N., Kishimoto, T., Iyo, M., Uchimura, N., Nishimura, R., Shimizu, N., Efficacy and safety of aripiprazole once-monthly in Asian patients with schizophrenia: a multicenter, randomized, double-blind, non-inferiority study versus oral aripiprazole. Schizophr. Res. 161:2–3 (2015), 421–428, 10.1016/j.schres.2014.12.013.
30. Iyer, S., Banks, N., Roy, M.-A., Tibbo, P., Williams, R., Manchanda, R., Chue, P., Malla, A., A qualitative study of experiences with and perceptions regarding long-acting injectable antipsychotics: part I-patient perspectives. Can. J. Psychiatr. Rev. Can. Psychiatr. 58:5 Suppl. 1 (2013), 14S–22S.
31. Janno, S., Holi, M.M., Tuisku, K., Wahlbeck, K., Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenia population. BMC Neurol., 5(1), 2005, 5, 10.1186/1471-2377-5-5.
32. Janssen Korea, L., NCT00992407 - an efficacy and safety study of long acting injectable risperidone and oral risperidone in participants with schizophrenia or schizoaffective disorder. https://clinicaltrials.gov/ct2/show/NCT00992407?term=NCT00992407&rank=1, 2014.
33. Janssen Pharmaceutical K.K, NCT00240708 - a study of the efficacy and safety of long-acting injectable risperidone and risperidone tablets in patients with schizophrenia. https://clinicaltrials.gov/ct2/show/record/NCT00240708, 2011.
34. Kane, J.M., Detke, H.C., Naber, D., Sethuraman, G., Lin, D.Y., Bergstrom, R.F., McDonnell, D., Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. AJP 167:2 (2010), 181–189, 10.1176/appi.ajp.2009.07081221.
35. Kane, J.M., Kishimoto, T., Correll, C.U., Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J. Clin. Epidemiol. 66:8 Suppl (2013), S37–S41, 10.1016/j.jclinepi.2013.01.012.
36. Kinross-Wright, J., Charalampous, K.D., A controlled study of a very long-acting phenothiazine preparation. Int. J. Neuropsychiatry(1), 1965, 66–70.
37. Kirson, N.Y., Weiden, P.J., Yermakov, S., Huang, W., Samuelson, T., Offord, S.J., Greenberg, P.E., Wong, B.J.O., Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia. J. Clin. Psychiatry 74:06 (2013), 568–575, 10.4088/JCP.12r08167.
38. Kishimoto, T., Nitta, M., Borenstein, M., Kane, J.M., Correll, C.U., Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J. Clin. Psychiatry 74:10 (2013), 957–965, 10.4088/JCP.13r08440.
39. Kishimoto, T., Robenzadeh, A., Leucht, C., Leucht, S., Watanabe, K., Mimura, M., Borenstein, M., Kane, J.M., Correll, C.U., Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr. Bull. 40:1 (2014), 192–213, 10.1093/schbul/sbs150.
40. Leucht, S., Kane, J.M., Kissling, W., Hamann, J., Etschel, E., Engel, R.R., What does the PANSS mean?. Schizophr. Res. 79:2–3 (2005), 231–238, 10.1016/j.schres.2005.04.008.
41. Leucht, S., Kissling, W., Davis, J.M., The PANSS should be rescaled. Schizophr. Bull. 36:3 (2010), 461–462, 10.1093/schbul/sbq016.
42. Leucht, C., Heres, S., Kane, J.M., Kissling, W., Davis, J.M., Leucht, S., Oral versus depot antipsychotic drugs for schizophrenia-a critical systematic review and meta-analysis of randomised long-term trials. Schizophr. Res. 127:1–3 (2011), 83–92, 10.1016/j.schres.2010.11.020.
43. Lieberman, J.A., Stroup, T.S., McEvoy, J.P., Swartz, M.S., Rosenheck, R.A., Perkins, D.O., Keefe, R.S.E., Davis, S.M., Davis, C.E., Lebowitz, B.D., Severe, J., Hsiao, J.K., Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353:12 (2005), 1209–1223, 10.1056/NEJMoa051688.
44. Llorca, P.M., Abbar, M., Courtet, P., Guillaume, S., Lancrenon, S., Samalin, L., Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry, 13, 2013, 340, 10.1186/1471-244X-13-340.
45. Maia-de-Oliveira, J.P., Bressan, R.A., Elkis, H., Machado-de-Sousa, J.P., Hallak, J.E.C., Why we should use long-acting injectable antipsychotics more frequently. Rev. Bras. Psiquiatr. 35:3 (2013), 217–218, 10.1590/1516-4446-2013-3503.
46. Mannaert, E., Vermeulen, A., Remmerie, B., Bouhours, P., Levron, J.C., Pharmacokinetic profile of long-acting injectable risperidone at steady-state: comparison with oral administration. L'Encéphale 31:5 Pt 1 (2005), 609–615.
47. McEvoy, J.P., The importance of early treatment of schizophrenia. Behav. Healthc. 27:4 (2007), 40–43.
48. McGrath, J., Saha, S., Chant, D., Welham, J., Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiol. Rev. 30 (2008), 67–76, 10.1093/epirev/mxn001.
49. Melmed, S., Casanueva, F.F., Hoffman, A.R., Kleinberg, D.L., Montori, V.M., Schlechte, J.A., Wass, J.A.H., Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96:2 (2011), 273–288, 10.1210/jc.2010-1692.
50. Misawa, F., Kishimoto, T., Hagi, K., Kane, J.M., Correll, C.U., Safety and tolerability of long-acting injectable versus oral antipsychotics: a meta-analysis of randomized controlled studies comparing the same antipsychotics. Schizophr. Res. 176:2–3 (2016), 220–230, 10.1016/j.schres.2016.07.018.
51. Moncrieff, J., Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatr. Scand. 114:1 (2006), 3–13, 10.1111/j.1600-0447.2006.00787.x.
52. Murray, R.M., Quattrone, D., Natesan, S., van Os, J., Nordentoft, M., Howes, O., Di Forti, M., Taylor, D., Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics?. Br. J. Psychiatry 209:5 (2016), 361–365, 10.1192/bjp.bp.116.182683.
53. Narasimhan, M., Un Pae, C., Masand, N., Masand, P., Partial compliance with antipsychotics and its impact on patient outcomes. Int. J. Psychiatry Clin. Pract. 11:2 (2009), 102–111, 10.1080/13651500600973568.
54. Nosé, M., Barbui, C., Tansella, M., How often do patients with psychosis fail to adhere to treatment programmes? A systematic review. Psychol. Med. 33:7 (2003), 1149–1160.
55. Ohkuma, T., Yagi, G., Yamashita, I., Takahashi, R., Mori, A., Kudo, Y., Kawakita, Y., Ichimaru, S., Yamaguchi, N., A phase III study of KD-136 (haloperidol decanoate: a long-acting neuroleptic) in the treatment of schizophrenia: the detailed analysis of multi-clinical double-blind comparative study of haloperidol decanoate with oral haloperidol preparation. Rinsho Hyoka 15:1 (1987), 37–72.
56. Otsuka Pharmaceutical Europe Ltd., 2008-002676-10 - a 38-week, multicenter, randomized, double-blind, active-controlled study to evaluate the efficacy, safety, and tolerability of an intramuscular depot formulation of aripiprazole (OPC-14597) as maintenance treatment in patients with schizophrenia. “ASPIRE EU” (Aripiprazole Intramuscular Depot Program in Schizophrenia), 2008 ( https://www.clinicaltrialsregister.eu/ctr-search/search?query=2008-002676-10).
57. Pantelis, C., Yucel, M., Wood, S.J., McGorry, P.D., Velakoulis, D., Early and late neurodevelopmental disturbances in schizophrenia and their functional consequences. Aust. N. Z. J. Psychiatry 37:4 (2003), 399–406.
58. Patel, M.X., Why aren't depot antipsychotics prescribed more often and what can be done about it?. Adv. Psychiatr. Treat. 11:3 (2005), 203–211, 10.1192/apt.11.3.203.
59. Patel, M., Haddad, P., Chaudhry, I., McLoughlin, S., David, A., Psychiatrist's use, knowledge and attitudes to first- and second-generation antipsychotic long-acting injections: comparisons over 5 years. J. Psychopharmacol. 24:10 (2010), 1473–1482, 10.1177/0269881109104882.
60. Perkins, D.O., Gu, H., Boteva, K., Lieberman, J.A., Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am. J. Psychiatry 162:10 (2005), 1785–1804, 10.1176/appi.ajp.162.10.1785.
61. Pietrini, F., Spadafora, M., Tatini, L., Talamba, G.A., Andrisano, C., Boncompagni, G., Manetti, M., Ricca, V., Ballerini, A., LAI versus oral: a case-control study on subjective experience of antipsychotic maintenance treatment. Eur. Psychiatry 37 (2016), 35–42, 10.1016/j.eurpsy.2016.05.008.
62. Intention to treat analysis and per protocol analysis: complementary information. Prescrire Int. 21:133 (2012), 304–306.
63. Quraishi, S., David, A., Depot haloperidol decanoate for schizophrenia. Cochrane Database Syst. Rev., 2, 2000, CD001361, 10.1002/14651858.CD001361.
64. Rifkin, A., Quitkin, F., Rabiner, C.J., Klein, D.F., Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year. Arch. Gen. Psychiatry 34:1 (1977), 43–47.
65. Sachs, G.S., Guille, C., Weight gain associated with use of psychotropic medications. J. Clin. Psychiatry 60:Suppl. 21 (1999), 16–19.
66. Sampson, S., (eds.) Cochrane Database of Systematic Reviews, 1996, John Wiley & Sons, Ltd., Chichester, UK.
67. Sampson, S., Hosalli, P., Furtado, V.A., Davis, J.M., Risperidone (depot) for schizophrenia. Sampson, S., (eds.) Cochrane Database of Systematic Reviews, 1996, John Wiley & Sons, Ltd., Chichester, UK.
68. Schooler, N.R., Levine, J., Severe, J.B., Brauzer, B., DiMascio, A., Klerman, G.L., Tuason, V.B., Prevention of relapse in schizophrenia. An evaluation of fluphenazine decanoate. Arch. Gen. Psychiatry 37:1 (1980), 16–24.
69. Schünemann, H., Brożek, J., Guyatt, G., Oxman, A., (eds.) GRADE Handbook: Handbook for Grading the Quality of Evidence and the Strength of Recommendations Using the GRADE Approach. Updated October 2013 The GRADE Working Group, 2013 ( http://gdt.guidelinedevelopment.org/app/handbook/handbook.html).
70. Stahl, S.M., Long-acting injectable antipsychotics: shall the last be first?. CNS Spectr. 19:1 (2014), 3–5, 10.1017/S1092852913001016.
71. StataCorp LP, Stata Statistical Software. 2015, Stata Corp. LP, College Station, TX (StataCorp LP. (da)).
72. Sterne, J.A., Gavaghan, D., Egger, M., Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J. Clin. Epidemiol. 53:11 (2000), 1119–1129.
73. Stevens, G.L., Dawson, G., Zummo, J., Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia. Early Interv. Psychiatry, 2015, 10.1111/eip.12278.
74. Subotnik, K.L., Casaus, L.R., Ventura, J., Luo, J.S., Hellemann, G.S., Gretchen-Doorly, D., Marder, S., Nuechterlein, K.H., Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia. A Randomized Clinical Trial. JAMA Psychiat. 72:8 (2015), 822–829, 10.1001/jamapsychiatry.2015.0270.
75. Suzuki, T., A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal. Expert Opin. Drug Deliv. 13:2 (2016), 253–264, 10.1517/17425247.2016.1115479.
76. Taylor, M., Ng, K.Y.B., Should long-acting (depot) antipsychotics be used in early schizophrenia? A systematic review. Aust. N. Z. J. Psychiatry 47:7 (2013), 624–630, 10.1177/0004867412470010.
77. The Cochrane Collaboration. Review Manager (RevMan). The Cochrane Collaboration, 2014, The Nordic Cochrane Centre, Copenhagen.
78. Tiihonen, J., Haukka, J., Taylor, M., Haddad, P.M., Patel, M.X., Korhonen, P., A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am. J. Psychiatry 168:6 (2011), 603–609, 10.1176/appi.ajp.2011.10081224.
79. Torrent Pharmaceuticals Ltd., I, CTRI/2012/04/002552 - a clinical trial to study the effect of olanzapine long acting injection with oral olanzapine in patients with schizophrenia. http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=2775&EncHid=&modi, 2012.
80. van Praag, H.M., Breetveld, J., van Mesdag-Etty, H., Westerhuis, R., Pen, A., Schut, T., A controlled comparative study of fluphenazine and fluphenazine enanthate in acute and chronic psychotic patients. Psychiatr. Neurol. Neurochir. 73:3 (1970), 165–175.
81. Vos, T., Flaxman, A.D., Naghavi, M., Lozano, R., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J.A., Abdalla, S., Aboyans, V., Abraham, J., Ackerman, I., Aggarwal, R., Ahn, S.Y., Ali, M.K., AlMazroa, M.A., Alvarado, M., Anderson, H.R., Anderson, L.M., Andrews, K.G., Atkinson, C., Baddour, L.M., Bahalim, A.N., Barker-Collo, S., Barrero, L.H., Bartels, D.H., Basáñez, M.-G., Baxter, A., Bell, M.L., Benjamin, E.J., Bennett, D., Bernabé, E., Bhalla, K., Bhandari, B., Bikbov, B., Abdulhak, A.B., Birbeck, G., Black, J.A., Blencowe, H., Blore, J.D., Blyth, F., Bolliger, I., Bonaventure, A., Boufous, S., Bourne, R., Boussinesq, M., Braithwaite, T., Brayne, C., Bridgett, L., Brooker, S., Brooks, P., Brugha, T.S., Bryan-Hancock, C., Bucello, C., Buchbinder, R., Buckle, G., Budke, C.M., Burch, M., Burney, P., Burstein, R., Calabria, B., Campbell, B., Canter, C.E., Carabin, H., Carapetis, J., Carmona, L., Cella, C., Charlson, F., Chen, H., Cheng, A.T.-A., Chou, D., Chugh, S.S., Coffeng, L.E., Colan, S.D., Colquhoun, S., Colson, K.E., Condon, J., Connor, M.D., Cooper, L.T., Corriere, M., Cortinovis, M., de Vaccaro, K.C., Couser, W., Cowie, B.C., Criqui, M.H., Cross, M., Dabhadkar, K.C., Dahiya, M., Dahodwala, N., Damsere-Derry, J., Danaei, G., Davis, A., de Leo, D., Degenhardt, L., Dellavalle, R., Delossantos, A., Denenberg, J., Derrett, S., Des Jarlais, D.C., Dharmaratne, S.D., Dherani, M., Diaz-Torne, C., Dolk, H., Dorsey, E.R., Driscoll, T., Duber, H., Ebel, B., Edmond, K., Elbaz, A., Ali, S.E., Erskine, H., Erwin, P.J., Espindola, P., Ewoigbokhan, S.E., Farzadfar, F., Feigin, V., Felson, D.T., Ferrari, A., Ferri, C.P., Fèvre, E.M., Finucane, M.M., Flaxman, S., Flood, L., Foreman, K., Forouzanfar, M.H., Fowkes, F.G.R., Franklin, R., Fransen, M., Freeman, M.K., Gabbe, B.J., Gabriel, S.E., Gakidou, E., Ganatra, H.A., Garcia, B., Gaspari, F., Gillum, R.F., Gmel, G., Gosselin, R., Grainger, R., Groeger, J., Guillemin, F., Gunnell, D., Gupta, R., Haagsma, J., Hagan, H., Halasa, Y.A., Hall, W., Haring, D., Haro, J.M., Harrison, J.E., Havmoeller, R., Hay, R.J., Higashi, H., Hill, C., Hoen, B., Hoffman, H., Hotez, P.J., Hoy, D., Huang, J.J., Ibeanusi, S.E., Jacobsen, K.H., James, S.L., Jarvis, D., Jasrasaria, R., Jayaraman, S., Johns, N., Jonas, J.B., Karthikeyan, G., Kassebaum, N., Kawakami, N., Keren, A., Khoo, J.-P., King, C.H., Knowlton, L.M., Kobusingye, O., Koranteng, A., Krishnamurthi, R., Lalloo, R., Laslett, L.L., Lathlean, T., Leasher, J.L., Lee, Y.Y., Leigh, J., Lim, S.S., Limb, E., Lin, J.K., Lipnick, M., Lipshultz, S.E., Liu, W., Loane, M., Ohno, S.L., Lyons, R., Ma, J., Mabweijano, J., MacIntyre, M.F., Malekzadeh, R., Mallinger, L., Manivannan, S., Marcenes, W., March, L., Margolis, D.J., Marks, G.B., Marks, R., Matsumori, A., Matzopoulos, R., Mayosi, B.M., McAnulty, J.H., McDermott, M.M., McGill, N., McGrath, J., Medina-Mora, M.E., Meltzer, M., Memish, Z.A., Mensah, G.A., Merriman, T.R., Meyer, A.-C., Miglioli, V., Miller, M., Miller, T.R., Mitchell, P.B., Mocumbi, A.O., Moffitt, T.E., Mokdad, A.A., Monasta, L., Montico, M., Moradi-Lakeh, M., Moran, A., Morawska, L., Mori, R., Murdoch, M.E., Mwaniki, M.K., Naidoo, K., Nair, M.N., Naldi, L., Narayan, K.V., Nelson, P.K., Nelson, R.G., Nevitt, M.C., Newton, C.R., Nolte, S., Norman, P., Norman, R., O'Donnell, M., O'Hanlon, S., Olives, C., Omer, S.B., Ortblad, K., Osborne, R., Ozgediz, D., Page, A., Pahari, B., Pandian, J.D., Rivero, A.P., Patten, S.B., Pearce, N., Padilla, R.P., Perez-Ruiz, F., Perico, N., Pesudovs, K., Phillips, D., Phillips, M.R., Pierce, K., Pion, S., Polanczyk, G.V., Polinder, S., Pope, C.A., Popova, S., Porrini, E., Pourmalek, F., Prince, M., Pullan, R.L., Ramaiah, K.D., Ranganathan, D., Razavi, H., Regan, M., Rehm, J.T., Rein, D.B., Remuzzi, G., Richardson, K., Rivara, F.P., Roberts, T., Robinson, C., de Leòn, F.R., Ronfani, L., Room, R., Rosenfeld, L.C., Rushton, L., Sacco, R.L., Saha, S., Sampson, U., Sanchez-Riera, L., Sanman, E., Schwebel, D.C., Scott, J.G., Segui-Gomez, M., Shahraz, S., Shepard, D.S., Shin, H., Shivakoti, R., Silberberg, D., Singh, D., Singh, G.M., Singh, J.A., Singleton, J., Sleet, D.A., Sliwa, K., Smith, E., Smith, J.L., Stapelberg, N.J.C., Steer, A., Steiner, T., Stolk, W.A., Stovner, L.J., Sudfeld, C., Syed, S., Tamburlini, G., Tavakkoli, M., Taylor, H.R., Taylor, J.A., Taylor, W.J., Thomas, B., Thomson, W.M., Thurston, G.D., Tleyjeh, I.M., Tonelli, M., Towbin, J.A., Truelsen, T., Tsilimbaris, M.K., Ubeda, C., Undurraga, E.A., van der Werf, M.J., van Os, J., Vavilala, M.S., Venketasubramanian, N., Wang, M., Wang, W., Watt, K., Weatherall, D.J., Weinstock, M.A., Weintraub, R., Weisskopf, M.G., Weissman, M.M., White, R.A., Whiteford, H., Wiersma, S.T., Wilkinson, J.D., Williams, H.C., Williams, S.R.M., Witt, E., Wolfe, F., Woolf, A.D., Wulf, S., Yeh, P.-H., Zaidi, A.K.M., Zheng, Z.-J., Zonies, D., Lopez, A.D., Murray, C.J.L., Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:9859 (2012), 2163–2196, 10.1016/S0140-6736(12)61729-2.
82. World Health Organization, WHO Model List of Essential Medicines: 19th List. 2015, World Health Organization ( http://www.who.int/medicines/publications/essentialmedicines/en. Accessed amended August 2015).
83. Wyatt, R.J., Neuroleptics and the natural course of schizophrenia. Schizophr. Bull. 17:2 (1991), 325–351.
84. Zhornitsky, S., Stip, E., Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: a systematic review. Schizophr. Res. Treat. 2012:2 (2012), 1–12, 10.1155/2012/407171.
85. Zuardi, A.W., Giampietro, A.C., Grassi, E.R., Matos Lima, A.A., Buoncompagno, E.M., Ribeiro Dos Santos, C.H., Bredariol, M.M., Fiestrino, A., Oliveria, M.A.S., Moura, D.S.P., KarniolI, G., Double-blind comparison between two forms of haloperidol: an oral preparation and a new depot decanoate in the maintenance of schizophrenic inpatients. Curr. Ther. Res. 34:2 (1983), 253–261.